Clinical Trial

IL-15 Enhanced NK Cell Therapy for Solid Tumors

Name: IL-15 Enhanced NK Cell Therapy for Solid Tumors — clinical trial record (NCT07621471)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

A single-arm, Phase 1 study evaluating safety, tolerability, and preliminary efficacy of IL-15 enhanced engineered NK cells in patients with refractory relapsed or metastatic solid tumors.

Trial Details

NCT Number	NCT07621471
Lead Sponsor	Genovn Therapeutics (Suzhou) Co., Ltd.
Conditions	Solid Tumors, Metastatic Cancer
Enrollment	12 participants
Start Date	2026-07-01
Primary Completion	2028-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-02